In 2015 a group of researchers led by New York University's Esther Blessing, PhD, investigated CBD's potential for treating anxiety. In a review of 49 studies, they found promising results and a need for more studies. "Preclinical" evidence (i.e., from animal studies) "conclusively demonstrates the efficacy of CBD in reducing anxiety behaviors related to several disorders," Dr. Blessing wrote. These include generalized anxiety disorder, PTSD, panic disorder, social anxiety disorder, and OCD.
The review notes that the human experimental findings have also supported the promising preclinical results, which also suggest "minimal effects and an excellent safety profile." But these findings are based on putting healthy subjects in anxiety-causing situations and measuring the effect of CBD on the anxiety response. Further studies are needed to establish whether treatment with CBD will have a similar effect in people who struggle with chronic anxiety, as well as what effects extended use of CBD may have. One can easily get the chill cbd gummies, high cbd capsules and cbd oil buy from stores.
"In total, the CBD has great potential as a treatment for many anxiety disorders indicated by the current evidence," said Dr. Blessing summarised, "which also needs the further study of the chronic and therapeutic effects in relevant clinical populations."
A group of Israeli researchers is exploring the use of CBD to reduce problem behaviors in children on the autism spectrum. A feasibility study involving 60 children found substantial improvements in behavioural outbursts, anxiety, and communication problems, as well as parent-reported stress levels. Researchers led by Adi Aran, director of the Pediatric Neurology Unit at Shaare Tzedek Medical Center, conducted a double-blind, randomized, placebo-controlled trial with 150 participants with autism. In this trial, just completed but not yet analyzed, patients were treated with CBD for three months.
In the US, research has been promoted through changes in guidelines and laws. In 2015 the DEA eased some regulatory requirements, which have made it difficult to study CBD as a Schedule 1 substance. Announcing the change, the DEA said, "Since CBD contains less than 1 percent THC and shows some potential medicinal value, there is great interest in studying it for medical applications."